Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.

06/23/2026, 3:20 PM • The Motley Fool

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.

04/27/2026, 1:00 PM • GlobeNewswire

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data center space, though it faces legal scrutiny. USA Rare Earth gained 56% YTD, supported by $1.6 billion in federal investment and strong cash position, though it remains an early-stage firm without proven profitability.

02/02/2026, 12:48 PM • Investing

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.

01/23/2026, 5:00 PM • GlobeNewswire

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is expected to close on January 23, 2026.

01/21/2026, 10:53 PM • GlobeNewswire

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals presented interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, showing promising results when combined with ipilimumab and nivolumab, with a 34% deep response rate and favorable safety profile.

10/17/2025, 10:00 AM • GlobeNewswire

Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 20 pharmaceutical companies are actively developing Interleukin-2 (IL-2) inhibitors to address autoimmune diseases and organ transplant procedures, with promising pipeline drugs in various clinical trial stages.

07/10/2025, 1:00 PM • GlobeNewswire